
The funding will be for a GLP-1 receptor agonist clinical programme for weight loss

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

The centre in California supports the company’s $32bn US investment

There are currently no approved human vaccines for Lyme disease

Litfulo delivered significant, clinically meaningful improvements for both face and body

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

The companies plan to research and develop 12 new cancer treatments

Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

Over three quarters of healthcare professionals call for co-created patient materials to drive engagement and trust, ultimately helping more patients benefit from prescribed treatments. Nearly 80% of healthcare professionals identify...

Over 800,000 people worldwide live with haemophilia